Best in Biotech 25 Jan 2024 Eight mental health biotech companies trying to make a difference to people’s lives …get better faster. The company’s clinical pipeline includes novel drug candidates for depression, post-traumatic stress disorder (PTSD), schizophrenia, and other mental health conditions. It also has its own biomarker platform… January 25, 2024 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Mar 2025 Depression drug trials are failing—and placebos are to blame …effect is,” the study read. Depression candidate Supernus’ SPN-820 fails in phase 2b clinical trial; Actinogen blames placebos This was seen with American biotech Supernus Pharmaceuticals’ depression candidate SPN-820, which… March 21, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 30 Jul 2024 Why is the immunology and inflammation market suddenly attracting a wave of investment? …biomedical advancements in the basic science of immunology combined with productizing therapeutic antibodies enabled the second wave. Here, doctors could finally direct an antibody at a defined immune target, allowing… July 30, 2024 - 13 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jan 2018 Swedish Biotech Pockets $6M as its Cancer Antibody Heads for the Clinic …to attack tumors by binding the CD40 co-stimulatory molecule on dendritic cells. The antibody may also kill cancer cells directly through a second mechanism. The candidate has already been tested… January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2017 PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody …round of investment in ChemomAb, an Israeli startup developing a monoclonal antibody to treat nonalcoholic steatohepatitis (NASH). ChemomAb’s antibody, CM-101, is fully humanized and targets a newly discovered protein that… December 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 14 Dec 2017 Belgian Biotech Raises $231M to Continue Developing its Antibody Therapies Argenx has smashed its target of $150M for its US offering, which will support its cancer and autoimmune disease antibodies through the clinic. Argenx develops antibody-based therapies for the treatment… December 14, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2019 Genmab’s Huge IPO Raises €450M to Develop Antibody Drugs The Danish biotech Genmab has made a big splash on the Nasdaq, raising a €450M ($506M) IPO to fuel its antibody drug programs in cancer, autoimmune diseases, and more. This… July 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 6 Jun 2019 Shares Drop 90% as Antibody for Inflammatory Skin Disease Fails Phase II …drug didn’t have any effect on the outcome. Hidradenitis suppurativa is a chronic disease that lasts for life and can be difficult to manage. InflaRx’s failed antibody was designed to… June 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2019 Janssen and Genmab Team Up Again for Another Potential Cancer Blockbuster …needs for patients,” stated the CEO of Genmab, Jan van de Winkel. “Pre-clinical data suggest that [the candidate antibody] could be superior to daratumumab for certain tumor cell types and… June 11, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Dec 2017 Belgian Antibody Proves Effective to Treat Myasthenia Gravis …Phase II trial with ARGX-113 (efgartigimod), in which the antibody therapy has proved to provide a significant improvement in patients with generalized myasthenia gravis, a form of the disease that… December 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Jul 2017 Roche and Ireland’s Biggest Biopharma Take Their Parkinson’s Antibody to Phase II Prothena and Roche are advancing their Parkinson’s antibody to Phase II, triggering a new milestone payment from what is proving a lucrative deal for Prothena. Prothena, the largest biopharma in… July 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 26 Jul 2024 Confo Therapeutics raises $60 million to focus on agonistic GPCR antibodies …GLP1R antibodies. One notable candidate, TB59-2, has shown strong preclinical efficacy in controlling blood glucose levels with a favorable pharmacokinetic profile. Another candidate, TB01-3, demonstrated effective blood glucose regulation in… July 26, 2024 - 8 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email